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To investigate clonal hematopoiesis associated gene mutations in vitro and to unravel the direct impact on the human stem and
progenitor cell (HSPC) compartment, we targeted healthy, young hematopoietic progenitor cells, derived from umbilical cord blood
samples, with CRISPR/Cas9 technology. Site-specific mutations were introduced in defined regions of DNMT3A, TET2, and ASXL1 in
CD34+ progenitor cells that were subsequently analyzed in short-term as well as long-term in vitro culture assays to assess self-
renewal and differentiation capacities. Colony-forming unit (CFU) assays revealed enhanced self-renewal of TET2 mutated (TET2mut)
cells, whereas ASXL1mut as well as DNMT3Amut cells did not reveal significant changes in short-term culture. Strikingly, enhanced
colony formation could be detected in long-term culture experiments in all mutants, indicating increased self-renewal capacities.
While we could also demonstrate preferential clonal expansion of distinct cell clones for all mutants, the clonal composition after
long-term culture revealed a mutation-specific impact on HSPCs. Thus, by using primary umbilical cord blood cells, we were able to
investigate epigenetic driver mutations without confounding factors like age or a complex mutational landscape, and our findings
provide evidence for a direct impact of clonal hematopoiesis-associated mutations on self-renewal and clonal composition of
human stem and progenitor cells.
Leukemia; https://doi.org/10.1038/s41375-021-01469-x
INTRODUCTION
Hematopoietic stem and progenitor cells (HSPCs) are continuously
generating mature blood cells. Although HSPCs divide rarely, they
can accumulate somatic mutations throughout their lifespan.
Mutations are acquired randomly in HSPCs with a rate of 0.07–0.86
mutations/year [1], and most of these spontaneous somatic
alterations do not affect cell function. Some mutations might
confer a proliferative and/or self-renewal advantage to the HSPCs,
leading to preferential expansion of specific clone(s). This
represents an effect mainly seen in the aging hematopoietic
system. Large sequencing studies have identified recurrent
mutations in blood cells of elderly individuals suffering from
non-hematologic diseases [2, 3] or healthy elderly individuals
[3, 4]. This phenomenon, termed clonal hematopoiesis of
indeterminate potential (CHIP), is defined by the presence of a
hematologic malignancy-associated gene mutation with a variant
allele frequency (VAF) of at least 2% [5]. The incidence of CHIP
increases in an age-related manner. Especially the epigenetic
regulators DNMT3A, TET2, and ASXL1 (DTA) have been identified to
be most commonly affected in association with CHIP [2–4]. We
and others have previously identified CHIP mutations in primitive
Lin−CD34+CD38− hematopoietic stem cells (HSCs) [6–8]. Several
groups have demonstrated that similar mutations can be found in
a pre-leukemic cell population in patients with full-blown acute
leukemia. These clones may survive chemotherapy, persist during
remission, and have a fitness advantage over normal HSCs [9–12].
To date, most knowledge about the impact of DTA mutations
on the HSPC compartment was obtained from murine models.
Conditional Dnmt3a−/− models revealed that murine HSCs block
differentiation in favor of self-renewal leading to a preferential
expansion of Dnmt3a−/− HSCs over wild-type cells [13]. In these
conditional Dnmt3a−/− mice, HSCs were continuously generated
after serial transplantation, but they were not able to generate
differentiated progenitor cells and continuously sustain hemato-
poiesis [14]. Tet2 is highly expressed in multipotent and myeloid-
committed progenitors isolated from mice. Disruption of Tet2
function is accompanied by altered hematopoiesis, upregulation
of HSC self-renewal and favors myeloid tumorigenesis [15–18]. In
human CD34+ cells it has been demonstrated that TET2 knock-
down leads to a shift from erythroid differentiation toward
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granulomoncytic differentiation [19]. ASXL1 has diverse roles in
histone modification and chromatin remodeling. Disruption of
Asxl1 in mice led to impaired lymphopoiesis as well as
myelopoiesis, but was not sufficient to induce leukemia [20].
Other groups reported that heterozygous loss of Asxl1 led to
development of MDS/MPN-like conditions [21]. In human CD34+
cells, ASXL1 mutations lead to impaired erythropoiesis [22].
Tothova and colleagues demonstrated that CD34+ cells from
adults carrying DTA mutations expanded in a xenograft model
and that distinct loss-of-function mutations were especially
prominent 5 months after transplantation [23].
DTA mutations co-occur frequently and presence of multiple
mutations increases the risk of hematologic cancer as compared
to single mutations [24–27]. However, there is only little data from
human combined knockout models, investigating additive effects
of co-mutations on the phenotype of human HSPCs.
Since there is increasing evidence that CHIP mutations might
occur very early in childhood, even in utero, interfere with branching,
and thereby affect population dynamics of hematopoiesis [28–30],
we aimed to investigate the impact of CHIP-associated mutations on
young healthy human HSPCs in vitro without confounding effects of
an aging microenvironment. So, we established a model to
specifically introduce DTA mutations in human CD34+ cells from
umbilical cord blood (CB). Established cell lines and mouse models as
well as CD34+ cells isolated from adult bone marrow have a diverse
genetic background, making it difficult to study the immediate
effects of introduced mutations, especially if the effects of
the specific mutations are subtle. In contrast, cells from umbilical
CB have several advantages over adult progenitor cells due to their
young age: (i) CB cells have accumulated less DNA damage, (ii) DNA
damage in the stem cell compartment (e.g., environmental toxicity,
nutritional stress, hypoxia) is minimized, (iii) CB cells are very stable
and robust in long-term cultures. Thus, human CB cells represent an
ideal cellular resource to study direct effects possibly caused by
genetic modifications [23, 31, 32]. Our study therefore provides novel
insights into the mechanisms of CHIP.
MATERIAL AND METHODS
Sample acquisition and primary cell culture
Cord blood (CB) of 11 donors was obtained in cooperation with the
Department for Obstetrics at Charité—Universitätsmedizin Berlin between
March 2019 and May 2020. The institutional Ethics Committee approved
the anonymous sampling of CB (EA2/234/18). The collection of umbilical
CB was performed ex utero by an obstetrician or trained midwife with an
umbilical CB collection kit from Macopharma (Mauvoux, France). CB
samples were handled anonymously to respect the privacy of mother and
child. Sample collection, handling and cell culture conditions are further
detailed in Supplementary Methods (Fig. S1).
CRISPR/Cas9-targeting via RNPs
CRISPR/Cas9-targeting of primary human stem and progenitor cells
(HSPCs) was carried out via ribonucleoprotein (RNP)-based delivery as
described before [33, 34]. In brief, recombinant Cas9 nuclease was
complexed with synthetic guide RNAs (Table S1, Synthego, Redwood City,
California, United States) in a molar ratio of 1:10. For homology directed
repair (HDR)-mediated specific mutations, Cas9 and sgRNA were mixed in a
1:5 molar ratio. The HDR template [12.5 pmol] was added directly before
electroporation. Electroporation was carried out using NEON transfection
system with 1600 V, 10ms, and 3 pulses. After electroporation, the cells
were cultured in short-term culture medium without antibiotics, before
seeding for different downstream experiments.
Sanger sequencing, T7 endonuclease assay, and quantitative
real-time PCR
DNA and RNA were isolated from cultured cells according to standard
protocols. More details on PCR and real-time PCR primers, Sanger
sequencing and the T7 endonuclease I (T7E1) assay are detailed in
Supplementary Methods.
SDS-PAGE and western blotting
Details are provided in Supplementary Methods (Table S2).
Colony forming and serial replating assays
Transfected cells were resuspended in IMDM (Thermo Fisher Scientific,
Waltham, Massachusetts, United States) supplemented with 2% FBS (Merck
Group, Darmstadt, Germany) at a final concentration of 1 × 104 cells/ml. For
duplicate assays 250 µl of the cell suspension was added to 2.5 ml
MethoCult® H4435 medium (STEMCELL™ Technologies), mixed thoroughly,
and 2 × 1ml of the cell suspension was dispensed into 35mm cell culture
dishes. The cells were incubated for 12 days at 37 °C. Colonies were
enumerated based on their morphology. To assess serial replating
capacity, quantified cultures were resuspended in IMDM/ 2% FBS, washed
twice, and viable cells were quantified. Depending on the cell concentra-
tion and viability, 1000–2500 cells were again plated in MethoCult®, as
described above. The process was repeated up to four times, or until no
colonies were detected.
Long-term culture initiating-cell assays
The feeder cell lines Sl/Sl and M2-10B4 were obtained as a kind gift (Prof.
Michael Heuser, Hannover Medical School, Germany). M2-10B4 are
engineered to express the human cytokines IL-3 (interleukin-3) and
G-CSF (granulocyte-colony stimulating factor) and Sl/Sl express the human
cytokines IL-3 and SCF (stem cell factor). Every third passage Geneticin and
Hygromycin B (both Thermo Fisher Scientific) were added to the culture
medium to select transduced cells [35, 36]. The feeder cells were mixed in a
1:1 ratio and seeded into collagen coated culture vessels before irradiation
with 80 Gy (rate: 2.5 Gy/min). After 24 h, the test cells were added in
human long-term culture medium (HLTM: MyeloCult H5100, STEMCELL™
Technologies,+1 µM Hydrocortisone, Merck Group). The cells were
cultured for up to nine weeks with half-medium change once a week.
After long-term culture, the complete vessel was harvested, viable cells
quantified via trypan blue exclusion, and the number of colony-forming
cells determined via colony-forming assay in MethoCult® H4435 as
described above.
Flow cytometry analysis of cell surface markers
Details are provided in Supplementary Methods (Table S3).
Dot blot analysis of 5-methylcytosin and
5-hydroxymethylcytosin levels
The detailed protocol is provided in Supplementary Methods.
Deep sequencing and indel analysis via CRISPRseq
DNA was extracted as described before and target sites were amplified to
result in 100–200 bp fragments [37]. Further sequencing and alignment
information are detailed in Supplementary Methods. The “Unknown indel
analysis”-pipeline of CRISPRseq was used [23]. Aligned reads were filtered
for those mapping to the DTA target amplicons. Variants were called with
DeepVariant (version 0.9.0) [38] in WGS mode limited. Only insertions and
deletions found at least ten times per sample were used for further
analysis.
RNA sequencing
Details are provided in Supplementary Methods.
RIMA analysis
Details are provided in Supplementary Methods.
Statistical analysis
Analysis of entropy was performed using the R package “entropy” [39].
Counts for each indel per sample and target were used as input for the
entropy calculation. All indels that were found more than ten times were
included in the analysis.
Data obtained from in vitro culture experiments was tested
for assumption of normal distribution by Shapiro–Wilk or
Kolmogorov–Smirnov test. Parametric tests were chosen for datasets
with assumption of normality. Tests and post-tests chosen for correction
of multiple testing errors (Benjamini–Hochberg, Dunn’s or Holm
method) are indicated in the figure legends. All differences were
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considered significant with alpha= 0.05. Statistics was performed by
use of GraphPad Prism 9.1.0.
RESULTS
CRISPR/Cas9 modeling in primary human HSPCs affects TET2
protein function
Mononuclear cells were isolated from freshly drawn umbilical CB.
Subsequently, CD34+ cells were collected by magnetic separation
and cultured for 2 days. After expansion, the cells were transfected
with RNPs targeting ASXL1 exon 13, TET2 exon 6, or DNMT3A exon
23 plus the HDR templates to introduce the mutation R882H in
DNMT3A exon 23 or a 8 bp deletion in ASXL1 exon 13. The
transfected cells were seeded for short-term culture experiments,
for CFU assays, or for long-term culture assays in parallel (Fig. 1A).
All in vitro culture experiments were carried out with bulk cells.
Before transfection, the enriched CD34+ cells were checked for
surface marker expression (Fig. 1B, Fig. S2) and at least 80% CD34+
enrichment was obtained for 9 out of 10 CB samples. Seven days
after transfection the editing efficiency was estimated via either T7
endonuclease assay (Fig. 1C) or Sanger sequencing and sequence
decomposition [40]. Sanger sequencing was repeated after 14 and
21 days of culture. We obtained a mean mutation efficiency of
38%, 39%, and 58% for DNMT3A, ASXL1, and TET2, respectively.
The 8 bp deletion in exon 13 of ASXL1 was included in the indel
frequency. The point mutation in DNMT3A exon 23 was introduced
in 33% of cells (Fig. 1D). The high mutation rate obtained via
CRISPR-modeling facilitated the work using bulk cell cultures,
which provides more insights in dynamics that involve wild-type
(WT) cells. Mutations and functional knockouts were analyzed on
mRNA and protein level for all targets without clear evidence of
mutant mRNA or protein decay (Fig. S3). In addition, a down-
regulation of 5-hydroxymethylcytosin conversion for TET2mut cells
could be confirmed (Fig. S4).
TET2mut cells show altered differentiation-associated
expression pattern and serial replating capacity in liquid
culture
By culturing the cells in liquid culture medium for 3 weeks,
immediate effects of introduced mutations on cell surface markers
and global gene expression were determined. After 7, 14, and
21 days, cell surface marker expression of the bulk cells were
analyzed via flow cytometry. We first examined cells transfected
with Cas9-RNP targeting all three genes simultaneously (multi KO)
to identify short-term effects. We observed a difference in CD66b-
and CD14-marker expression between the multi KO and the wild-
type cells, whereas for the other surface marker no pattern was
detectable (Fig. 2A and Fig. S5A). To dissect these immediate
effects further, seven biological replicates targeted with TET2-RNP
(TET2mut) and four samples targeted with ASXL1- or DNMT3A-RNPs
(ASXL1mut and DNMT3Amut, respectively) were analyzed in total.
For TET2mut, a significantly reduced CD66b-marker expression was
observed after 14 days of culture, which was not detected
anymore after 21 days of culture. CD14-marker expression was
significantly reduced in TET2mut for all time points (Fig. 2B, p <
0.05). We did not find a distinct expression pattern for ASXL1mut or
DNMT3Amut cells (Fig. S5B). Thus, in our model only the
introduction of TET2 mutations led to a delay in mature myeloid
surface marker expression in short-term liquid culture.
To investigate whether the introduced mutations affect
committed progenitor maturation, we performed colony forming
and replating assays. We did not observe significant differences in
Fig. 1 CRISPR/Cas9-mediated target-specific mutations in CD34+ cells from umbilical cord blood. A Experimental timeline from cord blood
to in vitro long-term culture experiments. p2/p3 depict the time points of methylcellulose replating. FACS: flow cytometry of cell surface
markers. B Exemplary cell surface marker distribution of CD34+ cells at the day of transfection. C T7 endonuclease I assay of each target to
determine CRISPR/Cas9 efficiency. Black arrowheads highlight the digested bands. T7E1: T7 endonuclease I, ex: exon, ctrl: Cells transfected
with Cas9 protein only. D Boxplot of predicted mutation frequencies as determined by Sanger sequencing and sequence decomposition
using ICE web tool. KO: insertions and deletions. SNV: hotspot mutation R882H.
F. Christen et al.
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the relative distribution of CFU types after the initial plating
(Fig. 2C), suggesting an equal distribution of different progenitor
types for all conditions. To assess the self-renewal capacity of the
progenitor cells, we performed a serial replating assay. An
enhanced serial replating capacity was only observed for TET2mut
cells (Fig. 2D, p < 0.01). This observation suggested that com-
mitted progenitors carrying a TET2 mutation gained enhanced
self-renewal capacities. However, exhaustion was observed after
three replating series (Fig. S6). Neither DNMT3Amut nor ASXL1mut
led to a comparable result (Fig. S7A).
Fig. 2 Differentiation and self-renewal capacities of mutated CD34+ cells. A Cell surface marker expression of multi KO vs. WT cells 7, 14,
and 21 days after transfection. One exemplary biological sample is shown. Frequencies were normalized to 100% for all depicted cell
populations. Bars and error bars show mean (SD) of two transfection replicates. B CD14 (left) and CD66b (right) surface marker expression of
TET2mut, multi KO, and wild-type cells 7, 14, and 21 days after transfection. Boxplots show all biological and technical replicates per condition.
*p < 0.05, **p < 0.01, Wilcoxon rank-sum test, corrected for multiple testing. C Relative distribution of CFU types for all biological and technical
replicates after the first seeding. BFU.E: burst-forming unit erythrocyte, CFU.E: colony-forming unit erythrocyte, CFU.GEMM: colony-forming
unit granulocyte, erythrocyte, macrophage, megakaryocyte, CFU.GM: colony-forming unit granulocyte, macrophage. D Serial replating assay
of TET2mut vs. WT cells. Boxplots show all technical and biological replicates. The number of passages is indicated above the plot. **p < 0.01,
Wilcoxon rank-sum test. E Differential Expression of genes in TET2 mutant cells. Global transcriptome of TET2mut cells vs. wild-type
counterparts was determined by RNA Sequencing of four replicates derived from two biological samples 7, 14, and 21 days after transfection.
Volcano blot shows differentially expressed (DE) genes after 21 days of both samples pooled in one analysis (Table S4). Log2-fold change is
shown on the x-axis and the y-axis shows the corresponding −log10 of the adjusted p values. F Longitudinal changes of gene expression
regulators after TET2 perturbation. Significantly DE genes (q < 0.05 either in the pooled analyses or in both of the samples in the same
direction) with a minimum log2-fold-change of ±0.4 were matched with a predefined list of transcriptional regulators of hematopoiesis
derived from the literature (Table S4). VENN diagram shows (common) transcriptional regulators differentially expressed at the different times
points. Arrows indicate up- or downregulation, double arrows indicate log2-fold-change >1/<−1. Transcriptional regulators associated with
myeloid differentiation are highlighted in bold, underlined genes are associated with stem cell properties.
F. Christen et al.
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In order to investigate perturbation of hematopoietic lineage
commitment, we performed RNA sequencing. Gene expression
analysis 7, 14, and 21 days after knockout of TET2 revealed increasing
alterations in the gene expression patterns over time, with a total
number of 84, 442, and 2256 differentially expressed genes after 7,
14, and 21 days, respectively (log2-FC <−0.4 or >0.4; q < 0.05).
Thereby, TET2 knockout affected a large number of genes associated
with the regulation of hematopoietic differentiation, such as an early
downregulation of CSF2RA. We found a common downregulation of
ETS1 after 7 days, which persisted after 14 and 21 days. Later events
were the upregulation of NOTCH3 and the downregulation of ID3.
After 21 days, a large number of myeloid transcription factors, such
as PU.1, FOG-1, GFI1, or GATA2, and myeloid lineage associated genes
were found perturbated in relation to TET2 wild-type cells (Fig. 2E, F,
Fig. S8, Table S4).
In summary, these results indicate that TET2 mutations have an
effect in terms of increased self-renewal but delayed differentia-
tion capacities of hematopoietic progenitor cells, especially
affecting the myeloid lineage, even in short-term culture
conditions and without further aging-associated factors.
DTA-mutations affect self-renewal capacities of HSPCs
Primitive progenitors can be investigated in long-term culture
initiating-cell assays [35]. The cells were cultured for up to nine
weeks on a feeder layer. After harvesting, the viable cell count was
determined for each replicate. Viable cell numbers in DNMT3Amut
and ASXL1mut samples differed strongly between donors. In
TET2mut and multi KO samples the variability was less pronounced.
For all mutant samples, except ASXL1mut, a significantly increased
number of viable cells compared to the wild type sample was
detected (Fig. 3A, p < 0.05). Thus, we showed the presence of
primitive progenitors and/or committed progenitors supporting
continuous production of mature myeloid cells in the samples.
These cells had enhanced self-renewal capacities compared to the
wild-type population. Flow cytometry analysis of the viable cells
confirmed that CD34+ progenitors were present after long-term
culture. In trend, the frequency of CD34+ cells was higher in the
mutants compared to the wild-type samples (DNMT3Amut: 1.31 ±
0.4%, ASXL1mut: 2.71 ± 1.77%, TET2mut: 0.52 ± 0.38%, WT: 0.10 ±
0.12%, Fig. 3B). After long-term culture, the majority of cells
expressed myeloid surface markers (Fig. 3C, D), irrespective of the
DTA genotype, which was expected since especially myelopoiesis
is supported in the applied culture condition.
Finally, to determine the number of primitive progenitors (also
termed long-term culture-initiating cells, LTC-IC) that were present
in the samples, a CFU assay was performed after long-term
culture. LTC-IC derived CFU were detected in all mutant samples
(Fig. 3E, p < 0.05). Interestingly, 71% of TET2mut (n= 17) as well as
multi KO (n= 7) samples were able to generate colonies. The
mean number of colonies per 20.000 test cells was 8.3 and 27.2 for
positive TET2mut and multi KO samples, respectively. Of the 9
investigated DNMT3Amut and ASXL1mut samples, we detected
colonies in 5 (56%) with a mean number of 15.8 and 4.8 colonies
per 20.000 test cells for positive DNMT3Amut and ASXL1mut
samples, respectively. Collectively, these data indicate that the
introduced mutations enhance the self-renewal capacities of
HSPCs. The differences in colony forming efficiency and colony
numbers indicate that the mutations effect the target cells in a
different manner and that self-renewal capacities are further
enhanced by the presence of multiple mutations.
Mutated cell clones expand preferentially in long term culture
To investigate whether distinct clones preferentially expanded
during the long-term culture period, a targeted deep
Fig. 3 Self-renewal capacities of mutated HSPCs after long-term culture. A Transfected cells were cultured for up to 9 weeks on irradiated
feeder cells. The number of viable cells was determined via trypan blue exclusion and normalized to the number of cells initially plated. B–D
Flow cytometry analysis of viable cells after long-term culture. One representative replicate of one biological sample is shown. E Long-term
culture initiating cell derived CFU assay. The number of LTC-IC derived CFU was normalized to the number of seeded cells. The y-axis was
square root transformed for better visualization. *p < 0.05, **p < 0.01, ***p < 0.001 Wilcoxon rank-sum test corrected for multiple testing.
F. Christen et al.
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sequencing was performed to determine the indel spectrum
within one sample. Further, distinct indel types were tracked
serially over various time points to analyze clonal behavior
within a sample. Target amplicons were sequenced with a mean
sequencing depth of ~24.000× followed by CRISPRseq muta-
tional analysis [23] (Fig. 4A and Table S5). Comparison of
mutation frequencies obtained via deep sequencing with
Sanger sequencing revealed that the frequencies were under-
estimated by Sanger sequencing (Fig. 4B). Interestingly, short-
term culture samples showed a higher number of distinct indel
types with decreasing numbers of distinct indels in samples
from methylcellulose and long-term cultures (Fig. 4C). The
overall mutation frequency did not change between the
different time points of sampling (Fig. S9). This indicated, that
especially in the selective culture conditions (methylcellulose
and long-term culture) clonal expansion took place. Next,
Shannon entropy analysis was performed to measure clonal
diversity within the samples. Samples from short-term cultures
had the highest entropy, meaning that the indel composition
was highly diverse in these samples. The entropy decreased for
methylcellulose and long-term culture samples (Fig. 4D). With
these results, we could demonstrate that distinct clones were
preferentially expanding in the selective culture conditions. In
order to address the question, whether non-randomly induced
indels, as outcome of genome editing induced by classical
microhomology-mediated end joining (c-MMEJ), show an
intrinsic selective advantage on our in vitro experiments, we
performed a Rational Indel Meta-Analysis (RIMA) [41]. C-MMEJ-
associated microhomology was found in 28% of all deletions,
with a range of 15.8% in 1–5 bp deletion to 58.5% in 11–20 bp
deletions. We also found a considerable increase of VAF for c-
MMEJ-associated deletions for all three DTA genotypes. How-
ever, the relative increase of clone size of MMEJ-associated
mutations did not differ from that of clones of non-MMEJ
offspring, suggesting that the observed bulk phenotype is
rather a result of more than one specific mutagenic mechanism.
(Fig. S10).
We further analyzed which types of mutations were primarily
found in expanding clones. To this end, 14 replicates from long-
term cultures were investigated for each mutation target. In 50%
of the investigated ASXL1mut long-term culture samples the
mutation frequency decreased compared to short-term culture
samples (Fig. S11A vs. S11B). Nevertheless, we observed distinct
indel types that were particularly prominent after long-term
culture (Fig. 5A and S11B) such as frameshift mutations at the
amino acid positions G642, G643, and G644 in the long-term
culture samples.
In DNMT3Amut long-term culture samples, two mutations
were predominantly found (Fig. 5B): the point mutation R882H
and a 1 bp insertion at position 25457243. The latter resulted in
a frameshift at codon R882 with a frameshift elongation of the
protein. In general, we observed a decrease in the overall
mutation frequency in one sample (Fig. S12). These data
showed that wild-type cells were not overgrowing mutated
cell clones. In 9 out of 14 long-term culture samples the 1 bp
insertion expanded while the point mutation either remained
stable or was overgrown. The point mutation overgrew other
indels in only two investigated samples (Fig. S11B). Distinct
mutations seemed to enhance the expansion capacities of cell
clones and especially distinct indel types conferred a prolif-
erative advantage to the cells.
TET2mut samples generally showed a stable overall mutation
frequency with few indels expanding over the long-term culture
period (Fig. 5C and Fig. S13). Thus, the indel composition was
much more diverse in TET2mut long-term culture samples
compared to ASXL1 and DNMT3A mutations.
Fig. 4 Indel composition of CRISPR-targeted HSPCs. A Width in bp as determined by CRISPRseq analysis of targeted deep sequencing data.
B Comparison of predicted indel frequencies per sample via CRISPRseq vs. Sanger sequencing and indel decomposition. C Number of indels
per sample as determined by CRISPRseq analysis. The samples are categorized by culture condition, independent of target and time point.
D Shannon entropy analysis as measure of diversity of found indels. Samples are categorized by culture condition, independent of target and
time point. **p < 0.01, ***p < 0.001 Wilcoxon rank-sum test corrected for multiple testing.




In this study, we investigated the impact of clonal hematopoiesis-
associated gene mutations on healthy HSPC development. We
used cells from umbilical CB to investigate the cell-intrinsic effects
of DTA mutations in short-term and long-term analyses without
confounding factors linked to an aging system.
For both murine [42] and human [19] in vitro cultures, impaired
myeloid differentiation has been described for TET2 mutant and
knockout cells. We could confirm that differentiation marker
expression of monocyte and granulocyte markers was delayed in
TET2mut cells. We further demonstrated a perturbated myeloid
expression phenotype in TET2 altered samples, an effect that has
been described previously [43]. The observed alterations of
myeloid transcription factor expression (e.g., GATA2, SPI1/PU.1,
GFI1, KLF1) might contribute to this effect indirectly, as well as
altered accessibility to their target motifs due to changes in the
DNA methylome by TET2 impairment itself [44]. Furthermore,
alterations associated with leukemogenesis, such as perturbation
of Notch Signaling [45, 46] or repression of SPI1/PU.1 and IRF8
transcription factors [47], were detected on a transcriptional level,
emphasizing a role of CHIP mutations in later transforming events.
With the model established here, we were able to demonstrate
enhanced self-renewal capacities for TET2mut committed progeni-
tors as determined via short-term serial replating assays. This is in
line with previous reports from murine knockout models
[15, 17, 48]. Enhanced serial replating capacities were also
reported for Dnmt3a knockout models in mice [49], which we
could not recapitulate in our experimental design. Our data
indicate that introduced DNMT3Amut and ASXL1mut do not have as
severe effects on the stem and progenitor cell compartment
in vitro as complete or conditional knockouts obtained from
in vivo models. Here, the lack of respective microenvironmental
niches might interfere with full phenotypic consequences.
However, in long-term cultures effects on self-renewal capacity
of the HSPC compartment could be demonstrated for all DTA
mutations. It has been reported that human cells carrying clonal
hematopoiesis-associated mutations are indeed able to support
long-term hematopoiesis as well as clonal expansion in trans-
planted mice [23].
We were able to observe increased colony-forming capacities in
all DTA-mutated CD34+ clones, with the strongest skewing in
multi KO samples, indicating a cooperative manner of mutations.
These findings are in line with published data that have shown an
increasing risk for hematologic cancer development and multiple
CHIP mutations [26].
We observed that especially DNMT3Amut and TET2mut cells are
able to support long-term myelopoiesis in vitro, leading to the
assumption that long-term HSCs in these conditions might have
enhanced self-renewal. ASXL1mut cells did not show increased cell
production after long-term culture, nevertheless the number of
LTC-IC derived CFUs was significantly increased for all mutants
compared to the control group. It therefore seems that a
proportion of mutated HSPCs gained enhanced self-renewal
capacities. We additionally found viable CD34+ cells in the
Fig. 5 Expansion of distinct cell clones in long-term culture. Representative examples of two replicates of two independent cord blood
samples (CB006 and CB009) after 7d and long-term culture. Distribution of mutations in (A) ASXL1mut, (B) DNMT3Amut, and (C) TET2mut are
shown before (T1) and after (T2) long-term culture. Different colors represent different mutations. Only the most prominent mutations are
labelled. In Figs. S11, S12, S13 all replicates are shown.
F. Christen et al.
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mutated long-term culture samples, indicating that these have
indeed self-renewed over the long-culture period of up to nine
weeks even in in vitro settings.
Interestingly, in ASXL1mut and DNMT3Amut samples, the viable
cell population after long-term culture was predominantly formed
from a small number of distinct cell clones. In ASXL1mut samples,
we found frameshift mutations at amino acids G642 to G644 to be
enriched. Frameshift mutations at these positions have been
reported frequently and are associated with a dismal prognosis
[6, 50–52]. In DNMT3Amut samples, we observed a high frequency
of the specifically introduced R882H mutation, a well-known
hotspot mutation in AML and to lesser extent in CHIP [6, 53].
However, this mutation did not lead to preferential expansion in
the majority of samples. In contrast, TET2mut samples from long-
term culture clones revealed a more heterogeneous clonal
composition within a sample as well as between samples.
Therefore, our data suggest that different cell populations profit
from the introduced mutations in a gene-specific fashion. Based
on sorted cell populations from individuals with clonal hemato-
poiesis, we and others previously have provided evidence that
DNMT3A mutations occur in very early HSCs whereas TET2
mutations favor especially myeloid-committed progenitors [6, 8].
The strength of our model is the use of healthy, young cells and
tracking the mutation frequency and expansion over the period of
up to 9 weeks, which permitted the preferential expansion of
either primitive or more committed progenitors independently of
confounding factors such as aging processes or pre-existing
somatic mutations. We were therefore able to demonstrate that
DTA mutations directly influence the behavior of human HSPCs
and confer enhanced self-renewal capacities to the cells,
independent of the physiological context. Our model thereby
provides a novel experimental setup, which offers functional
information about genetic determinants of early differentiation
processes in human HSPCs without the bias of already acquired
somatic mutations. It can now be applied for long-term in vitro
studies further exploring the role of DTA-mutations in response to
genotoxic agents. This application can help to better understand
clonal selection and the development of secondary hematopoietic
malignancies following anti-cancer treatment in patients with
clonal hematopoiesis.
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